resources

Evaluating the Impact of Hyaluronidase on Subcutaneous mAb Formulations Using the SCISSOR N3 Platform

Evaluating the Impact of Hyaluronidase on Subcutaneous mAb Formulations Using the SCISSOR N3 Platform

Application Notes

Preview - This content has been restricted to logged in users only.

Explore how SCISSOR evaluates hyaluronidase in subcutaneous biologic formulations. Case study shows differences in monoclonal antibody release behavior.
Evaluating the Impact of Hyaluronidase on Subcutaneous mAb Formulations Using the SCISSOR N3 Platform

Application Notes

This application note explores the in vitro evaluation of hyaluronidase in subcutaneous biologic formulations using the Subcutaneous Injection Site Simulator (SCISSOR). Using a monoclonal antibody formulation with and without hyaluronidase, the study demonstrates how SCISSOR can distinguish differences in release behavior and support excipient screening during subcutaneous formulation development.

Previous post